Immediate Impact

1 by Nobel laureates 3 from Science/Nature 63 standout
Sub-graph 1 of 21

Citing Papers

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020 Standout
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
2017 Standout
2 intermediate papers

Works of Serena Rupoli being referenced

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
2006
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
2001

Author Peers

Author Last Decade Papers Cites
Serena Rupoli 524 457 454 494 55 1.3k
Ingrid Simonitsch 359 486 292 239 54 1.4k
Mireia Camós 559 642 222 483 56 1.7k
Monia Lunghi 1066 346 186 621 60 1.7k
Kaaren K. Reichard 498 562 180 590 116 1.7k
AA Morley 386 741 142 460 23 1.5k
K. F. Wong 302 678 224 246 55 1.3k
Michihide Tokuhira 410 390 73 316 79 1.4k
S Pileri 159 441 233 206 35 1.3k
Judit Demeter 415 535 94 543 107 1.5k
M. Uppenkamp 356 553 108 378 64 1.6k

All Works

Loading papers...

Rankless by CCL
2026